Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis

George R. Thompson, James S. Lewis, David E. Nix, Thomas F. Patterson

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Coccidioidomycosis remains a significant clinical problem with substantial morbidity and mortality. The vast majority of infections are asymptomatic and the need for early primary therapy remains controversial. The use of triazole antifungals has improved tolerability of therapy but concerns about acute and long-term toxicities among available agents limit their use. In addition, recent findings of decreased in vitro fluconazole susceptibility to as many as 37% of Coccidioides spp. isolates raises concerns regarding optimal therapy for these infections as fluconazole is commonly used for therapy including central nervous system disease. Thus, new agents from novel antifungal classes are currently in preclinical and clinical development aimed at reducing toxicity and improving outcomes of these serious infections.

Original languageEnglish (US)
Pages (from-to)S76-S84
JournalMedical mycology
StatePublished - Jan 25 2019


  • Coccidioides
  • amphotericin
  • antifungal
  • azoles
  • coccidioidomycosis
  • fluconazole
  • isavuconazole
  • itraconazole
  • posaconazole
  • voriconazole

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis'. Together they form a unique fingerprint.

Cite this